By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boston Biomedical 

640 Memorial Drive

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-674-8600 Fax: 781-762-9863


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
GlycoMimetics (GLYC) Appoints Boston Biomedical CEO Patricia S. Andrews To Its Board Of Directors 6/12/2017 9:36:10 AM
Boston Biomedical Presents Data For Investigational Stemness Inhibitor Amcasertib At ASCO 2017 6/6/2017 7:51:49 AM
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity Of Investigational Stemness Inhibitor Napabucasin In Seven Tumor Types At ASCO 2017 6/5/2017 6:56:38 AM
Boston Biomedical Broadens Its Portfolio With A Focus On Strategic Technology Development As Stefan Schreck, PhD Joins The Senior Management Team 6/1/2017 8:06:43 AM
Boston Biomedical Presents New Preclinical Data At AACR 2017 Highlighting The Potential Role Of Cancer Stemness Inhibition 4/5/2017 6:24:47 AM
Boston Biomedical Initiates Canstem111p: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Metastatic Pancreatic Cancer 2/21/2017 6:32:50 AM
Boston Biomedical Announces First Clinical Data For Investigational WT1 Cancer Peptide Vaccine, DSP-7888, At American Society of Hematology Annual Meeting & Exposition 12/6/2016 10:46:35 AM
Boston Biomedical Announces Orphan Drug Designation For Napabucasin In Pancreatic Cancer 11/14/2016 6:27:53 AM
Boston Biomedical Initiates Canstem303c: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Pretreated Advanced Colorectal Cancer 10/21/2016 6:48:19 AM
Boston Biomedical Announces First Orphan Drug Designation For Napabucasin In Gastric/GEJ Cancer 6/23/2016 8:22:05 AM
123
//-->